To Evaluate the Adhesion of TK-254RX on Healthy Participants

Characterisation of Adhesion Performance of a Newly Developed Esflurbiprofen Topical System (EFTS) - a Phase I, Open-label Study in Healthy Subjects.

This study is a single-center, open-label, multiple-dose trial in healthy participants. The primary purpose of this study is to assess the adhesion of TK-254RX. Secondary purposes are to assess the safety of TK-254RX and the residual amount of the patch.

Study Overview

• Status: Recruiting
• Conditions: Healthy Participants
• Intervention / Treatment: Drug: Esflurbiprofen Topical System

• Study Type: Interventional
• Enrollment (Estimated): 90
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Yoshiyuki Taneoka; Phone Number: +813-6264-9123; Email: y-taneoka@teiyaku.co.jp

Study Locations

• Germany
  • Clogne
    • Am Sportpark Muengersdorf 6, Clogne, Germany, 50933
      • Recruiting
      • Deutsche Sporthochschule Köln
      • Contact: Eduard Ebert, Dr.
      • Contact: Hans-Georg Predel, Prof. Dr.; Phone Number: +49-221-4982-5270; Email: georg.predel@web.de

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• age: 18 to 64 years
• good state of health
• written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the participants enrolled in the clinical trial

Exclusion Criteria:

• any injury of body which may induce the restriction of body movement
• excessively hairy skin at application site
• current or anamnestic known skin disorder (e.g., atopic dermatitis (eczema), neurodermatitis, contact allergy, psoriasis, vitiligo, melanoma, squamous cell carcinoma) or shaving hair at application site, which might interfere with the safety or tolerability of the active ingredient
• history of excessive sweating/hyperhidrosis inclusive of application site
• participation in a clinical study within 30 days before inclusion in the study or concomitantly
• drug or alcohol abuse in the opinion of the investigator
• pregnant and lactating women

• women of child-bearing potential (WOCBP) who do not agree to apply highly effective contraceptive methods

  • Surgical sterilization
  • Hormonal contraception: combined (estrogen and progestogen containing) hormonal contraception, e.g., oral, intravaginal, transdermal, and progestogen-only hormonal contraception e.g. oral, injectable, implantable as well as intrauterine device (IUD) and intrauterine hormone-releasing system (IUS) each in combination with male condom to increase safety effect (double barrier method))
  • Bilateral tubal occlusion
  • Total abstinence throughout the study at the discretion of the Investigator
  • Periodic abstinence is not an acceptable method of contraception. An acceptable method of contraception must be maintained throughout the study.
  • A woman who is post-menopausal and not surgically sterile must have a negative urine pregnancy test at screening but will not need to comply with an acceptable method of contraception. Women are considered post-menopausal and not of childbearing potential if they had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL or had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman had been confirmed by follow up hormone level assessment.
• known hypersensitivity to Esflurbiprofen, R-flurbiprofen or one of the excipients of the EFTS
• existing cardiac and/or hematological diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
• existing hepatic and/or renal diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
• known liver or kidney insufficiency
• existing gastrointestinal diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
• history of relevant CNS and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders
• systolic blood pressure < 90 or > 139 mmHg
• diastolic blood pressure < 60 or > 89 mmHg
• pulse rate < 50 bpm or > 90 bpm
• ECG assessment by investigator: "conspicuous"
• participants who use any impermissible treatment or for whom restrictions apply
• subject is vulnerable such as detained or committed to an institution by a court of law or by legal authorities or close affiliation with the sponsor or the investigational site (e.g., a close relative of the investigator, dependent person (e.g., employee of or student at the investigational site), employee of the sponsor or affiliates)
• subjects who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
• subject with known bronchial asthma from previous history
• Laboratory values are out of normal range

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TK-254RX; TK-254RX will be applied to the left or right lower leg above the ankle once daily over 3 consecutive days	Drug: Esflurbiprofen Topical System; The total of one TK-254RX per day for 3 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Characterization of the patch adhesion	Measuring the patch adhesion area by percentage visually by site staff, with the patch remaining adhered	Day 1 to Day 4

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Recording adverse events and serious adverse events	Characterization of the occurrence of adverse events or serious adverse events of TK-254RX	Day 1 to Day 4
Residual amount of S-flurbiprofen	Residual amount of S-flurbiprofen in the used patch applied on Day 3	Day 3 to Day 4

Collaborators and Investigators

• Sponsor: Teikoku Seiyaku Co., Ltd.
• Collaborators: CRM Biometrics GmbH; SocraTec R&D GmbH; SocraMetrics GmbH; Clinsearch GmbH; HWI pharma services GmbH
• Investigators: Study Chair: Kenichi Nishiyama, Teikoku Seiyaku Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): January 19, 2026
• Primary Completion (Estimated): March 1, 2026
• Study Completion (Estimated): March 1, 2026

Study Registration Dates

• First Submitted: December 15, 2025
• First Submitted That Met QC Criteria: December 15, 2025
• First Posted (Actual): December 29, 2025

Study Record Updates

• Last Update Posted (Actual): January 28, 2026
• Last Update Submitted That Met QC Criteria: January 27, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: TK-254RX-0107; 2025-523577-42-00 (Ctis)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No